BPC-157

BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic peptide derived from a segment of the human gastric juice protein BPC. First described by Sikiric et al. in the early 1990s, it has been the subject of numerous preclinical studies investigating its effects on tissue repair, angiogenesis, and gastrointestinal mucosal protection. Despite a robust body of animal research, no completed human clinical trials with published pharmacokinetic data currently exist.

PubMed results: 201 · Human studies: 44 · Animal studies: 143

Ranges reflect protocols studied in published research and animal-model extrapolation. Presented for research purposes only, not a recommendation or instruction for human use.

No human clinical dosing has been established. Following ranges derived from animal study extrapolation.

• Subcutaneous Injection — standard range 250-500 mcg, Once daily. 4-12 weeks
• Oral — standard range 500 mcg, Once daily. Oral bioavailability demonstrated in animal models; human PK not established

Unknown in humans (low confidence)

Less than 30 minutes in animal models (IV). No human PK data.

• Tissue repair and wound healing (Strong preclinical): Multiple animal studies demonstrated accelerated healing of tendons, ligaments, muscle, bone, and skin
• Gastrointestinal mucosal protection (Strong preclinical): Shown to protect against various GI insults in rat models including NSAID-induced damage

• Injection site reactions — Mild, Anecdotal. No documented human side effects in published literature

• Active cancer (Theoretical / Preclinical): Pro-angiogenic properties raise theoretical concern about tumor vascularization

Lyophilized (powder): Refrigerated (2-8°C), Up to 24 months. Light sensitive: yes, store dark

Reconstituted (solution): Refrigerated (2-8°C), 4-6 weeks. Solvent: Bacteriostatic water

• NCT07437547 — BPC 157 for Acute Hamstring Muscle Strain Repair (PHASE2), status: RECRUITING. Indications: Hamstring Muscle Strain, Skeletal Muscle Injury
• NCT02637284 — PCO-02 - Safety and Pharmacokinetics Trial (PHASE1), status: UNKNOWN. Indications: Healthy Volunteers

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

BPC-157 has an extensive preclinical evidence base but zero completed human clinical trials with published pharmacokinetic data. All dosing information is extrapolated from animal studies. Amino Axiom rates this compound's evidence base as LIMITED.